Simparica Chewables

Simparica Chewables are flavored, chewable tablets administered once per month to kill adult fleas, treat and prevent flea infestations, treat and control tick infestations from 6 types of ticks (lone star tick, Gulf Coast tick, American dog tick, black-legged tick, brown dog tick, and Asian longhorned tick), and prevent infections that may cause Lyme disease by killing vector (deer) ticks.

Please note: Due to a manufacturer redesign, the same trusted formulation is receiving new, easier-to-read packaging. Your medication may arrive with this updated packaging, depending on manufacturer availability.

Ticks and fleas don’t slow down at the end of the month. Your dog’s tick and flea protection shouldn’t either. Simparica starts—and stays—strong all month long¹. Approved for dogs 6+ months old, weighing more than 2.8 lbs., Simparica is a tasty, pork liver-flavored monthly chewable that protects dogs from ticks and fleas for 35 days¹. It is approved to kill 5 types of ticks including the Gulf Coast tick, Brown dog tick, Deer tick, American dog tick, and Lone Star tick and is FDA-approved to block infections that may cause Lyme disease by killing deer ticks. Treatment may begin at any time of the year and may continue monthly, year-round without interruption. Feed one chewable; administer at monthly intervals. Simparica comes with a 100% satisfaction guarantee on prevention. If you feel that Simparica isn’t providing sufficient protection, please call Zoetis’ medical support team to discuss the satisfaction guarantee at 1-888-ZOETIS1. Automatic deliveries provide savings, convenience, and the peace of mind that your dog doesn’t miss a dose. Simparica is also eligible for the Zoetis Petcare Rewards Program. Enroll for free today and earn points with every dollar spent on eligible purchases to redeem for services at your vet. Available by veterinarian prescription only. Ask your vet if Simparica is right for your dog.

References:

1. Six RH, Everett WR, Young DR, et al. Efficacy of a novel oral formulation of sarolaner (Simparica®) against five common tick species infesting dogs in the United States. Vet Parasitol. 2016;222:28-32.

2. Honsberger NA, Six RH, Heinz TJ, et al. Efficacy of sarolaner in the prevention of Borrelia burgdorferi and Anaplasma phagocytophilum transmission from infected Ixodes scapularis to dogs. Vet Parasitol. 2016;222:67-72.

Dogs (6 months of age and older)

Sarolaner

Complete inactive ingredients list not provided by manufacturer.

Simparica Chewables

Isoxazoline ectoparasiticide

Simparica Chewable is a pork liver flavored chewable tablet.

*Contains pork, soy, lactose, corn, wheat

Zoetis

Weight Range	Sarolaner (per tablet)	Number of tablets administered
2.8 to 5.5 lbs	5 mg	One
5.6 to 11 lbs	10 mg	One
11.1 to 22 lbs	20 mg	One
22.1 to 44 lbs	40 mg	One
44.1 to 88 lbs	80 mg	One
88.1 to 132 lbs	120 mg	One

*For dogs over 132 lbs, administer the appropriate combination of tablets to cover your pet’s body weight.

*For complete product information, please review the full prescribing information in the manufacturer package insert.

Simparica Chewables should be given orally at monthly intervals year-round, or as otherwise directed by your veterinarian.

Manufacturer recommended usage:

Simparica (sarolaner) Chewables are given orally once a month at the recommended minimum dosage of 0.91 mg/lb (2 mg/kg).

Simparica Chewables can be offered by hand, in the food, or administered like other tablet medications.

Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes to ensure that part of the dose is not lost or refused.

If a dose is missed: administer Simparica immediately and resume a monthly dosing schedule. Do not give two doses at once.

Store in a cool, dry place at a controlled room temperature (at or below 86°F), with excursions permitted up to 104°F). Keep out of the reach of children and pets. Tablets should remain sealed in their original packaging and should only be taken out of the blister pack at the time of dosing. Store away from heat and direct sunlight.

Do not store in the bathroom, near the kitchen sink, or in damp places. The medicine may break down if exposed to heat or moisture.

Simparica is generally well tolerated, and side effects are considered uncommon when given at the recommended dosage. The most common side effects of this medication are vomiting, diarrhea, decreased appetite, and lowered energy level.

Contact your veterinarian immediately if your pet experiences persistent vomiting or diarrhea, or if you notice your pet has a seizure, tremors, extreme weakness, or decreased coordination (e.g., stumbling, difficulty walking).

Notify your veterinarian if your pet experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome.

If you notice anything unusual, please consult your veterinarian.

*For complete product information including warnings and precautions, please refer to the manufacturer package insert.

For oral use in dogs only- not for use in humans. Keep this and all drugs out of reach of children. Do not use Simparica in cats.

Simparica should not be used in dogs less than 6 months of age.

Keep Simparica in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion or overdose.

Sarolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.

The safe use of Simparica has not been evaluated in breeding, pregnant, or lactating dogs. Discuss the risks of using this medication with your veterinarian if your pet is in one of these groups.

Do not administer to animals with a known history or suspected allergy/hypersensitivity to any isoxazoline class drug, including this medication or any of its ingredients. Allergic reactions to medications may occur. Be sure to inform Vetsource and your veterinarian if your pet has any known drug sensitivities or allergies.

If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limited to): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching.

There are no documented drug or food interactions with Simparica Chewables.

Contact your veterinarian if your pet experiences any unusual reactions when different medications are given together.

Please ensure your veterinarian is aware of all medications and supplements that your pet is currently receiving. Your veterinarian may prescribe multiple medications, even if a potential drug interaction may occur. In these instances, your veterinarian may adjust the dosages or monitor your pet more closely.

If you are concerned that your pet has experienced an adverse reaction to this medication, please contact the manufacturer Zoetis at 888-963-8471 or Vetsource Pet Owner Care at 877-738-4443.

If you have any reason to suspect an overdose, call your doctor/veterinarian or the appropriate poison control resource immediately.

For humans:

The national toll-free Poison Help line, 1-800-222-1222, will connect you to your local poison center in case of emergency. This service is available nationwide and in most U.S. territories.

For animals:

The ASPCA Animal Poison Control Center is available 24 hours a day, 365 days a year at 888-426-4435.

Pet Poison Helpline® also provides a 24/7 animal poison control service at 855-764-7661.

All content, including the images and product description above, is intended for general informational purposes only and should not be considered a substitute for professional veterinary consultation, diagnosis, or treatment.

Consult your veterinarian for complete information about this product and how it fits into your pet's individual treatment plan.